BofA raised the firm’s price target on Teladoc (TDOC) to $8.75 from $7 and keeps a Neutral rating on the shares. Teladoc’s recent acquisitions of Catapult and Uplift provide optionality to drive higher revenue per member, but it will take both time and execution to improve the revenue growth outlook, the analyst tells investors in a research note. BofA remains cautious on full-year guidance and momentum into 2026 but views recent acquisitions as potential catalysts for growth.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TDOC:
- Teladoc’s Growth Challenges and Long-Term Potential: Analyst Maintains Hold Rating
- Omada Health initiated with an Overweight at Barclays
- Unusually active option classes on open June 25th
- Unusually active option classes on open June 24th
- Morning Movers: TD Synnex slips following second quarter results